Abstract
Purine nucleoside phosphorylase (PNP) is one of the enzymes comprising the purine salvage pathway, and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2-deoxyribonucleosides. The pivotal role of PNP in T-cell proliferation has been demonstrated in patients with inherited PNP deficiency, where T-cell levels may be 1-3percent of normal. This observation helped establish the critical role of PNP in T-cells and provided a rationale for developing inhibitors of PNP. Inhibitors of PNP may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohns disease and T-cell cancers. In this manuscript, the x-ray crystal structure of the PNP enzyme is described. Results of a structure-based drug design program aimed at designing small-molecule inhibitors of PNP are also described. Of the many classes of compounds synthesized, studied and reviewed, only one, the 3-pyridinylmethyl-9-deazaguanine (BCX-34, 39) analog has been used in clinical trials. Both topical and oral formulations of BCX-34 were studied in psoriatic patients and the results of these clinical trials are described.
Keywords: Enzyme Purine Nucleoside Phosphorylase, Human immunodeficiency virus, HIV, PNP enzyume, PNP inhibitors, X ray crystallographic analysis
Current Pharmaceutical Design
Title: Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis
Volume: 6 Issue: 9
Author(s): Philip E. Morris,Jr. and George A. Omura
Affiliation:
Keywords: Enzyme Purine Nucleoside Phosphorylase, Human immunodeficiency virus, HIV, PNP enzyume, PNP inhibitors, X ray crystallographic analysis
Abstract: Purine nucleoside phosphorylase (PNP) is one of the enzymes comprising the purine salvage pathway, and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2-deoxyribonucleosides. The pivotal role of PNP in T-cell proliferation has been demonstrated in patients with inherited PNP deficiency, where T-cell levels may be 1-3percent of normal. This observation helped establish the critical role of PNP in T-cells and provided a rationale for developing inhibitors of PNP. Inhibitors of PNP may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohns disease and T-cell cancers. In this manuscript, the x-ray crystal structure of the PNP enzyme is described. Results of a structure-based drug design program aimed at designing small-molecule inhibitors of PNP are also described. Of the many classes of compounds synthesized, studied and reviewed, only one, the 3-pyridinylmethyl-9-deazaguanine (BCX-34, 39) analog has been used in clinical trials. Both topical and oral formulations of BCX-34 were studied in psoriatic patients and the results of these clinical trials are described.
Export Options
About this article
Cite this article as:
Morris,Jr. E. Philip and Omura A. George, Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis, Current Pharmaceutical Design 2000; 6 (9) . https://dx.doi.org/10.2174/1381612003400083
DOI https://dx.doi.org/10.2174/1381612003400083 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicolegal Aspects of Disclosure of Side Effects of Biologic Drugs in Rheumatology: A Pilot Study
New Emirates Medical Journal Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
Current Medicinal Chemistry Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Relationship Between Vitamin D Deficiency and Chronic Low Back Pain in Postmenopausal Women
Current Rheumatology Reviews Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Tachykinins and the Cardiovascular System
Current Drug Targets Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Natural Anticoagulant Proteins in the Regulation of Autoimmunity: Potential Role of Protein S
Current Pharmaceutical Design Stem Cells in MDR-TB and XDR - TB
Current Respiratory Medicine Reviews Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile
Current Drug Safety Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic: Protein Kinase Inhibitors for the Treatment of Inflammatory Disease (Guest Editor: Mark R. Player)]
Current Topics in Medicinal Chemistry On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Immunomodulatory and Anti-inflammatory Properties of Artesunate in Experimental Colitis
Current Medicinal Chemistry What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
Current Medicinal Chemistry Ginsenoside Rb1 Directly Scavenges Hydroxyl Radical and Hypochlorous Acid
Current Pharmaceutical Design